Explore

Rapid Read Rapid Read
Mount Sinai Researchers Uncover Structure of Brain Protein, Opening New Avenues for Epilepsy Treatment

Mount Sinai Researchers Uncover Structure of Brain Protein, Opening New Avenues for Epilepsy Treatment

Scientists at the Icahn School of Medicine at Mount Sinai have achieved a breakthrough in neurological research by revealing the high-resolution structure of NBCn2, a brain protein associated with epilepsy and other neurological disorders. Using cryo-electron microscopy, the team captured detailed images of NBCn2, which regulates acid-base balance in brain cells. This discovery has led to the development of the first compounds capable of inhibiting NBCn2's activity, potentially paving the way for new treatments for neurological conditions. The study, published in Nature Communications, highlights the protein's role in transporting sodium and carbonate ions to control brain cell activity. Researchers used the structural data to design compounds that reduced electrical signaling between neurons in experiments with mouse brain tissue.
Trendline Trendline
Nona Biosciences Partners with Medical University of Vienna for Antibody Development

Nona Biosciences Partners with Medical University of Vienna for Antibody Development

Nona Biosciences Partners with Medical University of Vienna for Antibody Development
Trendline Trendline
Biotech Innovations: Multiomics and Human Cell-Based Research Advancements

Biotech Innovations: Multiomics and Human Cell-Based Research Advancements

Biotech Innovations: Multiomics and Human Cell-Based Research Advancements
Rapid Read Rapid Read
Department of Health and Human Services Launches Genesis Mission to Advance AI in Biomedical Research

Department of Health and Human Services Launches Genesis Mission to Advance AI in Biomedical Research

The Department of Health and Human Services (HHS), in collaboration with the White House Office of Science and Technology Policy, has announced the Genesis Mission, a national initiative aimed at leveraging artificial intelligence and advanced computing to accelerate biomedical research. This mission is part of a broader effort to secure U.S. leadership in key technologies over the coming decade. The National Institutes of Health (NIH) is spearheading the Bio Genesis Mission, which focuses on using AI to address complex biological challenges, such as predicting living systems and accelerating drug discovery. The initiative also aims to improve health outcomes by fostering public-private partnerships and innovative policy approaches.
Trendline Trendline
AI Model for Protein Engineering Aims to Revolutionize Biomanufacturing

AI Model for Protein Engineering Aims to Revolutionize Biomanufacturing

AI Model for Protein Engineering Aims to Revolutionize Biomanufacturing
Rapid Read Rapid Read
Cold Spring Harbor Laboratory Scientists Revive Vancomycin to Combat Superbugs

Cold Spring Harbor Laboratory Scientists Revive Vancomycin to Combat Superbugs

Researchers at Cold Spring Harbor Laboratory (CSHL), led by Professor John Moses, have developed a method to restore the effectiveness of vancomycin, a powerful antibiotic that had become less effective against certain drug-resistant bacteria. The team utilized a technique called diversity oriented clicking (DOC) to create a library of over 150 compounds. In collaboration with Scripps Research, they identified a small molecule, pghi-4, which inhibits a bacterial enzyme called secreted antigen A (SagA). This inhibition allows vancomycin to regain its ability to kill drug-resistant strains of E. faecium, a pathogen known for causing severe infections. The research highlights the potential of using existing drugs in combination with new molecules to combat antibiotic resistance.
Rapid Read Rapid Read
SORLA Protein Shows Promise in Protecting Against Tau Tangles in Alzheimer's Research

SORLA Protein Shows Promise in Protecting Against Tau Tangles in Alzheimer's Research

Researchers at Sanford Burnham Prebys have discovered that the protein SORLA may offer protection against the harmful effects of tau tangles, which are associated with Alzheimer's disease and other neurodegenerative conditions. In a study published in Science Advances, the team led by Timothy Huang, PhD, demonstrated that overexpression of SORLA in a mouse model reduced tau hyperphosphorylation, synaptic loss, and glial hyperactivation. These findings suggest that SORLA could be a potential therapeutic target for treating tauopathies, which are characterized by the accumulation of tau proteins that disrupt neuronal circuits. The study involved crossbreeding mice to produce extra human SORLA protein, which showed a protective effect against tau-related damage.
Trendline Trendline
Dimension Capital Secures $800 Million for AI-Driven Biotech Investments

Dimension Capital Secures $800 Million for AI-Driven Biotech Investments

Dimension Capital Secures $800 Million for AI-Driven Biotech Investments
Trendline Trendline
Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models

Challenges in Drug Discovery Highlight Need for Human-Centric Preclinical Models
Trendline Trendline
Dimension Capital Launches $800M Fund to Boost Science and Compute Ventures

Dimension Capital Launches $800M Fund to Boost Science and Compute Ventures

Dimension Capital Launches $800M Fund to Boost Science and Compute Ventures
Trendline Trendline
AbelZeta's C-CAR168 Receives EMA PRIME Designation for Lupus Treatment

AbelZeta's C-CAR168 Receives EMA PRIME Designation for Lupus Treatment

AbelZeta's C-CAR168 Receives EMA PRIME Designation for Lupus Treatment
Reuters Reuters
US to spend $5 billion on health, construction research powered by AI

US to spend $5 billion on health, construction research powered by AI

By Courtney Rozen WASHINGTON, July 22 (Reuters) - The U.S. will spend $5 billion to tackle long-standing scientific problems across multiple fields using AI, the Trump administration said in a statement on Wednesday.